Exhibit 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

	2014			2013															% Change
	1Q			1Q			2Q			3Q			4Q			Full Year			1Q

Sales	$	10,264		$	10,671		$	11,010		$	11,032		$	11,319		$	44,033		-4	%

Costs, Expenses and Other
Materials and production	3,903			3,959			4,284			4,104			4,607			16,954			-1	%
Marketing and administrative	2,734			2,987			3,140			2,803			2,982			11,911			-8	%
Research and development	1,574			1,907			2,101			1,660			1,836			7,503			-17	%
Restructuring costs	125			119			155			870			565			1,709			5	%
Equity income from affiliates	(124		)	(133		)	(116		)	(102		)	(53		)	(404		)	-7	%
Other (income) expense, net	(39		)	282			201			172			157			815			*
Income Before Taxes	2,091			1,550			1,245			1,525			1,225			5,545			35	%
Income Tax (Benefit) Provision	360			(66		)	310			375			410			1,028
Net Income	1,731			1,616			935			1,150			815			4,517			7	%
Less: Net Income Attributable to Noncontrolling Interests	26			23			29			26			34			113
Net Income Attributable to Merck & Co., Inc.	$	1,705		$	1,593		$	906		$	1,124		$	781		$	4,404		7	%
Earnings per Common Share Assuming Dilution	$	0.57		$	0.52		$	0.30		$	0.38		$	0.26		$	1.47		10	%

Average Shares Outstanding Assuming Dilution	2,971			3,053			3,010			2,960			2,959			2,996
Tax Rate	17.2		%	-4.3		%	24.9		%	24.6		%	33.5		%	18.5		%

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FIRST QUARTER 2013

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2b

				Acquisition-		Restructuring		Adjustment
	GAAP			Related Costs (1)		Costs (2)		Subtotal			Non-GAAP

Sales	$	10,671									$	10,671

Costs, Expenses and Other
Materials and production	3,959			1,184		43		1,227			2,732
Marketing and administrative	2,987			23		17		40			2,947
Research and development	1,907			30		15		45			1,862
Restructuring costs	119					119		119			—
Equity income from affiliates	(133		)					—			(133		)
Other (income) expense, net	282							—			282
Income Before Taxes	1,550			(1,237	)	(194	)	(1,431		)	2,981
Taxes on Income	(66		)					(439		)(3)	373
Net Income	1,616							(992		)	2,608
Less: Net Income Attributable to Noncontrolling Interests	23							—			23
Net Income Attributable to Merck & Co., Inc.	$	1,593						$	(992	)	$	2,585
Earnings per Common Share Assuming Dilution	$	0.52									$	0.85

Average Shares Outstanding Assuming Dilution	3,053										3,053
Tax Rate	-4.3		%								12.5		%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions. Amounts included in marketing and administrative expenses reflect merger integration costs. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items, as well as a benefit of approximately $160 million associated with the resolution of a previously disclosed federal income tax issue.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FIRST QUARTER 2014

(AMOUNTS IN MILLIONS)

Table 3a

	Global					U.S.					International
	1Q14		1Q13		% Change	1Q14		1Q13		% Change	1Q14		1Q13		% Change

TOTAL SALES (1)	$	10,264	$	10,671	-4	$	4,146	$	4,215	-2	$	6,119	$	6,457	-5
PHARMACEUTICAL	8,451		8,891		-5	3,130		3,256		-4	5,321		5,635		-6
Primary Care and Women’s Health
Cardiovascular
Zetia	611		629		-3	323		334		-3	288		295		-3
Vytorin	361		394		-8	120		156		-23	241		238		1
Diabetes
Januvia	858		884		-3	474		462		3	384		422		-9
Janumet	476		409		16	213		197		8	263		212		24
General Medicine & Women’s Health
NuvaRing	168		151		11	103		89		15	65		62		5
Follistim AQ	110		122		-10	34		41		-17	76		81		-6
Dulera	102		68		49	97		66		47	5		3		90
Implanon	102		84		21	60		42		41	42		42
Hospital and Specialty
Hepatitis
Peglntron	112		126		-11	4		9		-53	108		117		-7
Victrelis	59		110		-46	5		37		-87	54		73		-25
HIV
Isentress	390		362		8	190		187		2	199		175		14
Hospital
Cancidas	166		162		3	7		7		4	159		156		2
Invanz	114		110		4	60		54		11	55		57		-3
Noxafil	74		65		13	20		18		8	55		47		16
Bridion	73		63		16						73		63		16
Primaxin	71		84		-15	3		4		-10	68		80		-16
Immunology
Remicade	604		549		10						604		549		10
Simponi	157		108		45						157		108		45
Other
Cosopt / Trusopt	99		105		-7	1		4		-76	98		102		-4
Oncology
Emend	122		116		5	70		66		7	52		50		4
Temodar	83		216		-62			108		*	83		108		-23
Diversified Brands
Respiratory
Nasonex	312		385		-19	133		150		-11	179		235		-24
Singulair	271		337		-20	5		1		*	266		336		-21
Clarinex	62		61		2	6		6		11	55		55		1
Other
Cozaar / Hyzaar	205		267		-23	6		11		-47	199		256		-22
Arcoxia	128		121		6						128		121		6
Fosamax	123		137		-10	4		5		-23	119		132		-9
Propecia	74		68		8	5		6		-26	69		62		12
Zocor	64		82		-21	5		6		-22	60		76		-21
Remeron	50		52		-4	1		1		-35	50		51		-3
Vaccines
Gardasil	383		390		-2	271		247		10	113		142		-21
ProQuad, M-M-R II and Varivax	280		272		3	240		246		-2	39		26		49
RotaTeq	169		162		4	130		130			39		32		20
Zostavax	142		168		-15	129		152		-15	13		16		-18
Pneumovax 23	101		111		-9	83		86		-4	18		25		-29
Other Pharmaceutical (2)	1,175		1,361		-14	328		328			845		1,030		-18
ANIMAL HEALTH	813		840		-3	177		231		-23	636		609		4
CONSUMER CARE	546		571		-4	390		400		-2	156		171		-9
Claritin OTC	170		177		-4	139		146		-5	31		31		-2
Other Revenues (3)	454		369		23	448		328		37	6		41		-85
Astra	147		262		-44	147		262		-44

* 100% or greater

(1) Only select products are shown.

(2) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $98 million and $53 million on a global basis for first quarter 2014 and 2013, respectively.

(3) Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the company divested a substantial portion of its third-party manufacturing sales. Other revenues in the first quarter of 2014 include $232 million of revenue recognized in connection with the sale of U.S. Saphris rights.

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3b

																			%
																			Change
	1Q14			1Q13			2Q13			3Q13			4Q13			Full Year			1Q

TOTAL PHARMACEUTICAL	$	8,451		$	8,891		$	9,310		$	9,475		$	9,760		$	37,437		-5
United States	3,130			3,256			3,689			4,148			3,761			14,854			-4
% Pharmaceutical Sales	37.0		%	36.6		%	39.6		%	43.8		%	38.5		%	39.7		%
Europe (1)	2,478			2,465			2,343			2,276			2,535			9,619			1
% Pharmaceutical Sales	29.3		%	27.7		%	25.2		%	24.0		%	26.0		%	25.7		%
Japan	835			1,034			948			893			1,074			3,949			-19
% Pharmaceutical Sales	9.9		%	11.6		%	10.2		%	9.4		%	11.0		%	10.5		%
Latin America	538			596			676			628			667			2,567			-10
% Pharmaceutical Sales	6.4		%	6.7		%	7.3		%	6.6		%	6.8		%	6.9		%
Asia Pacific	809			822			874			799			870			3,365			-1
% Pharmaceutical Sales	9.6		%	9.2		%	9.4		%	8.4		%	8.9		%	9.0		%
China	282			271			297			242			293			1,103			4
Eastern Europe/Middle East Africa	415			439			479			431			534			1,883			-5
% Pharmaceutical Sales	4.9		%	4.9		%	5.1		%	4.5		%	5.5		%	5.0		%
Canada	200			245			257			253			276			1,030			-18
% Pharmaceutical Sales	2.4		%	2.8		%	2.8		%	2.7		%	2.8		%	2.8		%
Other	46			34			45			47			43			170			34
% Pharmaceutical Sales	0.5		%	0.4		%	0.5		%	0.5		%	0.4		%	0.5		%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.

FIRST QUARTER 2014

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE, NET - GAAP

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 4

EQUITY INCOME FROM AFFILIATES

	1Q14		1Q13
ASTRAZENECA LP	$	98	$	125
Other (1)	26		8
TOTAL	$	124	$	133

(1) Includes results for Sanofi Pasteur MSD.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a “NET” basis.

	1Q14		1Q13
GARDASIL	$	64	$	73
OTHER VIRAL VACCINES	25		29
ROTATEQ	17		14
HEPATITIS VACCINES	9		8
ZOSTAVAX	7		—
Other Vaccines	95		106
TOTAL SANOFI PASTEUR MSD SALES	$	217	$	230

OTHER (INCOME) EXPENSE, NET

	1Q14			1Q13
INTEREST INCOME	$	(61	)	$	(57	)
INTEREST EXPENSE	188			184
EXCHANGE LOSSES	34			212
Other, net	(200		)	(57		)
TOTAL	$	(39	)	$	282